Search results
Kluczowe wnioski. W uwzględnionych badaniach porównano stosowanie remdesiwiru wraz ze standardową opieką zdrowotną lub standardową opieką zdrowotną (z placebo lub bez niego) u hospitalizowanych chorych na COVID-19. Pacjenci hospitalizowani z umiarkowanym lub ciężkim przebiegiem COVID-19.
- English
• For adults hospitalised with COVID-19, remdesivir probably...
- Bahasa Malaysia
Tiada kajian menilai orang tanpa gejala COVID-19. Purata...
- Deutsch
In keiner Studie wurden Personen mit symptomloser...
- Remdesivir
中度至重度 covid-19 的住院患者. 瑞德西韋可能對 28 天、60 天後的死亡或 150...
- English
Find a pharmacy near you to pick up PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) for COVID-19 treatment. See risks, benefits and BOXED WARNINGS.
Treatment Locator. Find COVID-19 Medications. The map below displays pharmacies, clinics, and other locations with safe and effective COVID-19 medications. These medications require a prescription from a healthcare provider.
The COVID-19 Therapeutics Locator is an interactive map that assists health care providers with identifying licensed and authorized locations where patients can fill prescriptions or receive therapy. The locator displays public locations with available courses of U.S. Government-procured COVID-19 therapeutics.
Patients with mild-to-moderate disease who are at high risk for progression to severe COVID-19. One RCT compared treatment with three days of intravenous (IV) remdesivir (200 mg on day one followed by 100 mg on days two and three) initiated within 7 days of symptom onset or no remdesivir in unvaccinated patients [158].
7 wrz 2021 · There has been one published cost-effectiveness analysis of remdesivir looking at cost-effective threshold prices finding that a treatment course of remdesivir should be approximately $19,000 to...
22 kwi 2022 · Today, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date.
